SUBSCRIBE
SUBSCRIBE

Palleon Pharmaceuticals

NEWS
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Genetown
Palleon Pharma Bursts Onto the Scene With $47.6 Million and a New R&D Approach
October 4, 2017
 · 
2 min read
IN THE PRESS
Press Releases
Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 8, 2024
 · 
3 min read
Genetown
Palleon to Present New Findings on Colorectal Tumor Microenvironment Identified with its HYDRA Platform at Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 31, 2023
 · 
2 min read
Genetown
Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023
August 28, 2023
 · 
2 min read
Drug Development
Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial
June 22, 2023
 · 
2 min read
Drug Development
Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor
April 18, 2023
 · 
3 min read
Genetown
Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day
February 7, 2023
 · 
1 min read
Genetown
Palleon Announces Issuance of a U.S. Patent for Use of Antibody Sialidase Conjugates
October 13, 2022
 · 
3 min read
Genetown
Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase
October 12, 2022
 · 
1 min read
Drug Development
Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 11, 2022
 · 
2 min read
Business
Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology
October 5, 2022
 · 
3 min read
Load More
JOBS